Skip to main content
Anhui Sunhere Pharmaceutical Excipients Co.,Ltd logo

Anhui Sunhere Pharmaceutical Excipients Co.,Ltd — Investor Relations & Filings

Ticker · 300452 ISIN · CNE100001ZH5 LEI · 300300ORPCFM06UN9W97 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,200 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300452

About Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

https://www.shanhe01.com

Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. specializes in the research, development, production, and distribution of high-quality pharmaceutical excipients. The company provides a comprehensive portfolio of products essential for solid oral dosage forms, including microcrystalline cellulose, hydroxypropyl methylcellulose, croscarmellose sodium, magnesium stearate, and various film coating systems. With a focus on innovation and quality control, the firm maintains advanced manufacturing facilities that comply with international Good Manufacturing Practice (GMP) standards. Its products are designed to meet the rigorous requirements of the global pharmaceutical industry, supporting drug formulation through improved stability, solubility, and delivery. The company leverages extensive R&D expertise to offer customized solutions and technical support, ensuring compliance with major pharmacopoeias such as USP, EP, and CP.

Recent filings

Filing Released Lang Actions
安徽天禾律师事务所关于安徽山河药用辅料股份有限公司2025年度股东会的法律意见书
Regulatory Filings Classification · 89% confidence The document is a legal opinion letter (“法律意见书”) issued by a law firm concerning the convening, attendance, voting procedures, and results of a 2025 annual shareholders’ meeting. It serves as a legal certification/opinion rather than the meeting’s presentation materials (AGM information), the actual voting results announcement alone, or a substantive corporate financial report. Under the certification rule, any attestation or confirmation letter—even if it includes meeting results—is classified as a general regulatory filing (RNS).
2026-05-13 Chinese
2025年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is titled “2025年度股东会决议公告” and provides detailed voting results for each agenda item at the 2025 Annual General Meeting, including vote counts, percentages, and legal opinions. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-13 Chinese
董事及高级管理人员薪酬管理制度（2026年4月）
Remuneration Information Classification · 91% confidence The document is a detailed internal policy (‘薪酬管理制度’) for structuring, determining, and governing remuneration for the company’s directors and senior management. It outlines compensation principles, approval procedures, pay components, incentive arrangements, performance testing, and clawback provisions. This aligns exactly with the “Remuneration Information” category (Code: DEF 14A) which covers reports detailing compensation for top executives and directors. It is not an announcement of a report (RPA), nor a governance charter broadly (CGR), but specifically addresses pay policies and processes.
2026-04-22 Chinese
关于公司为全资子公司提供担保的公告
Capital/Financing Update Classification · 85% confidence The document is an announcement by Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd. regarding the company providing a joint liability guarantee for its wholly-owned subsidiary’s credit facility of up to RMB 150 million. It details the guarantee arrangements, board approvals, subsidiary financials, and related terms. This is not a general financial report, management change, or legal proceeding, but clearly pertains to financing activities (guarantee for borrowing). Therefore, it falls under Capital/Financing Update (CAP).
2026-04-22 Chinese
关于公司向全资子公司提供财务资助的公告
Capital/Financing Update Classification · 85% confidence The document is an exchange listing announcement by 安徽山河药用辅料股份有限公司 describing the board-approved provision of financial assistance (a zero-interest loan) of up to RMB 100 million to its wholly-owned subsidiary. It details the financing amount, terms, purpose, approval process and risk controls. This is a corporate financing activity disclosure rather than an earnings release or dividend notice. Therefore it falls under Capital/Financing Update (CAP).
2026-04-22 Chinese
第六届董事会第十次会议决议公告
Regulatory Filings Classification · 85% confidence The document is a Board of Directors meeting resolution announcement, detailing approvals of various reports, profit distribution plan, governance items, and the convening of the 2025 shareholders’ meeting. It is not a change in board or management composition (MANG), nor a full annual report or other structured report category. It is a regulatory announcement of board resolutions, fitting the general Regulatory Filings category.
2026-04-22 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.